Adipose-derived allogeneic mesenchymal stem cell therapy - Steminent BiotherapeuticsAlternative Names: Adipose-derived allogeneic mesenchymal stem cells - Steminent; Allogeneic adipose-derived mesenchymal stem cells - Steminent Biotherapeutics; Mesenchymal stem cells - Steminent; Stemchymal®
Latest Information Update: 16 Sep 2015
At a glance
- Originator Steminent Biotherapeutics
- Class Stem cell therapies
- Mechanism of Action Cell replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Ataxia
Most Recent Events
- 16 Sep 2015 Phase-II clinical trials in Ataxia in Taiwan (IV)